Explore a selection of our essential drug information below, or:
Identification
- Summary
Antihemophilic factor human is a Factor VIII replacement therapy used to treat hemophilia A.
- Brand Names
- Hemofil, Koate, Wilate
- Generic Name
- Antihemophilic factor human
- DrugBank Accession Number
- DB13192
- Background
Antihemophilic factor human, also known as Coagulation Factor VIII or Anti-Hemophilic Factor (AHF), is a non-recombinant, lyophilized concentrate of coagulation factor VIII, an endogenous protein and essential component of the coagulation cascade. Antihemophilic factor is manufactured with reduced amounts of von Willebrand Factor antigen (VWF:Ag) and purified from extraneous plasma-derived protein by affinity chromatography. The small amount of VWF:Ag is used to purify factor VIII complex and then removed from the final preparation. The final purified concentrate contains albumin as a stabilizer.11. The complex was developed by CSL Behring or Baxter Healthcare Corporation and approved in the 90s.
Endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as a co-factor to Factor IX. Activation of Factor IX leads to a cascade of signals that results in activation of Factor X, which then results in the conversion of prothrombin to thrombin, and as a result, leads to the conversion of fibrinogen to fibrin, the fibrous protein that creates the scaffold of the clot. Replacement of Factor VIII is essential for the treatment of Hemophilia A, which is caused by mutations in the Factor VIII gene, leading to a functional deficiency or complete loss of protein. Congenital loss or deficiency of Factor VIII results in the physiologic impairment of the coagulation clotting cascade, and as a result, leads to easy bruising and bleeding. Bleeding can range in severity from minor concerns, such as nosebleeds, to more serious events such as hemorrhaging in the joints, brain, or digestive tract 6.
Exogenous replacement of Factor VIII is currently the cornerstone of Hemophilia treatment and is used for the prophylaxis and control of bleeding episodes. Treatment has drastically improved since the 1960s when Factor VIII protein was primarily purified from human plasma, rather than being produced through recombinant DNA technology. Unfortunately, purification of protein from human plasma carries an increased risk of transmission of blood-borne diseases such as HIV and Hepatitis, which in part contributed to the Tainted Blood Scandal in the 1980s and 1990s 7,8.
Other drug products with similar structure and function to Antihemophilic factor human include Moroctocog alfa, which is produced by recombinant DNA technology and is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function and Efmoroctocog alfa, which is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared with conventional factor VIII due to conjugation to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein 7.
Antihemophilic factor human is approved by the Food and Drug Administration for use in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes Label.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Blood factors - Protein Structure
- Protein Chemical Formula
- Not Available
- Protein Average Weight
- 480000.0 Da (active (coagulant activity))
- Sequences
>>>antihemophilic factor<<<< MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFN TSVVYKKTLFVEFTVHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAV GVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSH VDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRD AASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNH RQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNE EAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLA PDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTL LIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGP TKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDE NRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILS IGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRG MTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTI PENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPS PGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSST SNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEE NNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTN KTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRL NHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSG QGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDN LHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYE GAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNT SQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTDTQWSKNMKHLTPSTLTQIDYNEKE KGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASY RKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLP KPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRP GKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSL NACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEE IDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR AQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASR PYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDV DLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRA PCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGH VFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKC QTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMII HGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFN PPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFA TWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFL ISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRM EVLGCEAQDLY
Download FASTA Format- Synonyms
- Antihemophilic factor VIII human
- Antihemophilic factor, human
- Antihemophilic factor, human (monoclonal)
- Antihemophilic factor,human
- F8 protein, human
- Factor VIII (antihaemophilic factor)
- Factor VIII (human)
- factor VIII, human
- Human coagulation factor VIII
Pharmacology
- Indication
The human antihemophilic factor is indicated for the cases of hemophilia A, also known as classical hemophilia for the prevention and control of hemorrhagic episodes.12 If surgery is needed in patients with hemophilia A there is a need of correction of the clotting abnormality. In this cases, the human antihemophilic factor may be administered followed by intermittent maintenance doses.11 The hemophilia A is characterized by the deficiency of the coagulation factor VIII that results in prolonged blood flow after injury or surgery as well as recurrent bleeding.9
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to manage Hemorrhagic episodes Combination Product in combination with: Von Willebrand factor human (DB13133) •••••••••••• Used in combination to manage Hemorrhagic episodes Combination Product in combination with: Von Willebrand factor human (DB13133) •••••••••••• Used in combination to manage Hemorrhagic episodes Combination Product in combination with: Von Willebrand factor human (DB13133) •••••••••••• Management of Hemorrhagic episodes •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
The human antihemophilic factor assists in the convertion of prothrombin to thrombin.10 Its administration generates the formation of a complex constituted by the Factor IXa, Factor X and the antihemophilic factor which triggers the normal coagulation cascade for the formation of blood clots.1 The human antihemophilic factor is increased in the plasma thus enabling temporary correction of the hemophilia A bleeding.13 Its effect is reported as the normalization of the partial thromboplastin time.14
- Mechanism of action
The human antihemophilic factor replaces the coagulation factor VIII. It acts as a co-factor for factor IX to activate factor X in the intrinsic pathway of blood coagulation.13,14
Target Actions Organism ACoagulation factor IX activatorHumans ACoagulation factor X activatorHumans - Absorption
After intravenous administration of the human antihemophilic factor the values of Cmax, AUC and Tmax were 100 IU/ml, 1450 IU h/ml and 0.43 h respectively. In a second clinical trial, the treatment was administered for six months and the values of Cmax, AUC and Tmax were 99 units/ 100 ml, 1471 units h/ 100ml and 16 h, respectively.14
- Volume of distribution
The pharmacokinetic profile of the human antihemophilic factor needed to be studied by the two-compartment theory as not all of it stays just in blood plasma. The central and peripheral volume of distribution in adults weight an average of 68 kg were 2.81 L and 1.90 L respectively.3
- Protein binding
The human antihemophilic factor is retained mainly in the blood as its major function is to start the coagulation cascade.
- Metabolism
The metabolism of the human antihemophilic factor is identical to the normal inactivation and elimination pathway of the natural coagulation factor VIII. After activation, the human antihemophilic factor gets metabolized by activated protein C in R336 and R562 and this action inactivates this cofactor. The proteolysis generates two major fragments which are recognized by an anti-factor VIII A2 domain antibody. This process is followed by a further degradation into smaller fragments.4
- Route of elimination
Intravenous administration of human antihemophilic factor is rapidly eliminated primarly through the reticuloendothelial system.5
- Half-life
The mean half-life of human antihemophilic factor administered in hemophilic A patients is 14.8 hours.13
- Clearance
The reported clearance for the administration of antihemophilic factor is 0.15 L/h in adults with an average weight of 68 kg. In the same study, there was a separation of the intercompartment clearance which is 0.16 L/h. The clearance rate was reported to be significantly decreased with increasing age and significantly increased in patients that presented a blood type of gourp O.3
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The highest toxicity is the risk of viral hepatitis transmition as well as intravascular hemolyisis can occur if large or frequent doses are used in blood groups A, B or AB.10
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Abciximab. Acenocoumarol The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Acenocoumarol. Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor human. Alteplase The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Alteplase. Aminocaproic acid The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor human. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Factorate Inj 15unit/ml Powder, for solution 15 unit / mL Intravenous Armour Pharmaceutical Co. 1984-12-31 1999-12-15 Canada 
Hemofil M Kit; Powder, for solution 500 [iU]/10mL Intravenous Takeda Pharmaceuticals America, Inc. 1988-02-23 Not applicable US 
Hemofil M Kit; Powder, for solution 1700 [iU]/10mL Intravenous Takeda Pharmaceuticals America, Inc. 1988-02-23 Not applicable US Hemofil M Kit 50 [iU]/1mL Intravenous Baxter Healthcare Corporation 2010-04-13 2010-04-13 US Hemofil M Kit; Powder, for solution 250 [iU]/10mL Intravenous Takeda Pharmaceuticals America, Inc. 1988-02-23 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aleviate Human Coagulation Factor VIII/VWF Complex, Powder for Injection Antihemophilic factor human (50 IU/ML) + Von Willebrand factor human (120 IU/ML) Injection Intravenous DKSH MALAYSIA SDN. BHD. 2020-09-08 Not applicable Malaysia 
ALPHANATE Antihemophilic factor human (250 IU/5mL) + Von Willebrand factor human (300 IU/5mL) Injection, powder, for solution Intravenous Grifols Italia S.P.A. 2014-07-08 2021-04-11 Italy 
ALPHANATE Antihemophilic factor human (2000 IU/10mL) + Von Willebrand factor human (2400 IU/10mL) Injection, powder, for solution Intravenous Grifols Italia S.P.A. 2019-02-12 Not applicable Italy Alphanate Antihemophilic factor human (1000 unit / vial) + Von Willebrand factor human (1200 unit / vial) Powder, for solution Intravenous Grifols Biologicals Llc Not applicable Not applicable Canada Alphanate Antihemophilic factor human (2000 unit / vial) + Von Willebrand factor human (2400 unit / vial) Powder, for solution Intravenous Grifols Biologicals Llc Not applicable Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image FACTOR VIII 500 IU FLAKON, 1 ADET Antihemophilic factor human (500 iu) Injection Intravenous VİTALİS SAĞLIK ÜRÜNLERİ DANIŞMANLIK VE TİC. A.Ş. 2013-03-12 Not applicable Turkey 
FAKTOR VIII 8Y 500 IU IV INFUZYON ICIN LIYOFILIZE TOZ ICEREN FLAKON, 1 ADET Antihemophilic factor human (500 iu) Injection, powder, lyophilized, for solution Intravenous VİTALİS SAĞLIK ÜRÜNLERİ DANIŞMANLIK VE TİC. A.Ş. 2015-02-17 Not applicable Turkey
Categories
- ATC Codes
- B02BD02 — Coagulation factor viii
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 839MOZ74GK
- CAS number
- Not Available
References
- General References
- Nogami K: Bispecific antibody mimicking factor VIII. Thromb Res. 2016 May;141 Suppl 2:S34-5. doi: 10.1016/S0049-3848(16)30361-9. [Article]
- Morfini M: The History of Clotting Factor Concentrates Pharmacokinetics. J Clin Med. 2017 Mar 20;6(3). pii: jcm6030035. doi: 10.3390/jcm6030035. [Article]
- Hazendonk H, Fijnvandraat K, Lock J, Driessens M, van der Meer F, Meijer K, Kruip M, Gorkom BL, Peters M, de Wildt S, Leebeek F, Cnossen M, Mathot R: A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica. 2016 Oct;101(10):1159-1169. doi: 10.3324/haematol.2015.136275. Epub 2016 Jul 6. [Article]
- Warren DL, Morrissey JH, Neuenschwander PF: Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: generation of an inactive factor VIII cofactor. Biochemistry. 1999 May 18;38(20):6529-36. doi: 10.1021/bi983033o. [Article]
- Bjorkman S, Berntorp E: Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40(11):815-32. doi: 10.2165/00003088-200140110-00003. [Article]
- Franchini M, Mannucci PM: Hemophilia A in the third millennium. Blood Rev. 2013 Jul;27(4):179-84. doi: 10.1016/j.blre.2013.06.002. Epub 2013 Jun 28. [Article]
- Frampton JE: Efmoroctocog Alfa: A Review in Haemophilia A. Drugs. 2016 Sep;76(13):1281-1291. doi: 10.1007/s40265-016-0622-z. [Article]
- Santagostino E: A new recombinant factor VIII: from genetics to clinical use. Drug Des Devel Ther. 2014 Dec 12;8:2507-15. doi: 10.2147/DDDT.S73241. eCollection 2014. [Article]
- Konkle B., Huston H. and Fletcher S. (2017). Gene Reviews. University of Washington..
- Hodgson B and Kizior R. (2014). Saunders Nursing Drug Handbook. Elsevier.
- CSL Behring [Link]
- Hemofil M [Link]
- Dailymed [Link]
- Dailymed [Link]
- External Links
- FDA label
- Download (326 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Treatment Severe Hemophilia A 1 somestatus stop reason just information to hide Not Available Recruiting Not Available Hemophilia A 1 somestatus stop reason just information to hide Not Available Terminated Not Available Hemophilia A 1 somestatus stop reason just information to hide Not Available Unknown Status Not Available Von Willebrand's Disease 1 somestatus stop reason just information to hide Not Available Withdrawn Prevention Severe Hemophilia A 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous; Parenteral 1000 IU Injection, powder, for solution Intravenous; Parenteral 2000 IU Injection, powder, for solution Intravenous; Parenteral 250 IU Injection, powder, for solution Intravenous; Parenteral 500 IU Injection, powder, for solution 100 IU/ml Injection, powder, for solution Parenteral 100 I.E./ml Injection Intravenous 1000 iu Powder Intravenous 1000 IU Injection, powder, for solution Parenteral 200 I.E./ml Powder Intravenous 250 IU Injection Intravenous 500 iu Powder Intravenous 500 IU Injection, powder, lyophilized, for solution Intravenous 250 IU Solution Injection, powder, for solution Intravenous 50 iu/mL Injection, powder, for solution 1000 iu/10ml Injection Intravenous 1000 iu/10ml Injection, powder, for solution 500 iu/10ml Injection Intravenous 500 iu/10ml Injection, powder, lyophilized, for solution Intravenous 1000 iu/10ml Injection, powder, lyophilized, for solution Intravenous 500 iu/5ml Powder, for solution Intravenous 15 unit / mL Injection, powder, lyophilized, for solution Intravenous 1500 iu/15ml Injection, powder, lyophilized, for solution Intravenous 250 iu/10ml Injection, powder, for solution Intravenous 250 IU/10mL Injection, powder, lyophilized, for solution Intravenous 500 iu/10ml Injection, powder, for solution Intravenous 1000 iu/vial Injection, powder, for solution Intravenous 250 iu Injection, powder, for solution Intravenous 500 iu Injection Intravenous Injection, powder, for solution Parenteral Injection, powder, lyophilized, for solution Intravenous 1000 iu Injection, powder, lyophilized, for solution Parenteral 250 IU Injection, powder, for solution Parenteral 50 I.E./ml Injection, powder, lyophilized, for solution Intravenous 500 mg Injection, powder, lyophilized, for solution Intravenous 500 iu Kit Intravenous 100 [iU]/1mL Kit Intravenous 170 [iU]/1mL Kit Intravenous 25 [iU]/1mL Kit Intravenous 50 [iU]/1mL Kit; powder, for solution Intravenous 1000 [iU]/10mL Kit; powder, for solution Intravenous 1700 [iU]/10mL Kit; powder, for solution Intravenous 250 [iU]/10mL Kit; powder, for solution Intravenous 500 [iU]/10mL Powder, for solution Intravenous 1700 unit / vial Injection, powder, for solution Intravenous Powder, for solution Intravenous 700 unit / vial Injection, solution Intravenous 1200 iu/10ml Injection, powder, lyophilized, for solution Intravenous 600 iu Injection, powder, lyophilized, for solution; kit Intravenous 1000 [iU]/10mL Injection, powder, lyophilized, for solution; kit Intravenous 250 [iU]/5mL Injection, powder, lyophilized, for solution; kit Intravenous 500 [iU]/5mL Kit Intravenous 1000 [iU]/10mL Kit Intravenous 250 [iU]/5mL Kit Intravenous 500 [iU]/5mL Solution Parenteral 250 UI Injection, solution, concentrate Intravenous 250 IU/5mL Injection, powder, for solution 250 IU Injection, powder, for solution 500 IU Injection, powder, for solution Intravenous 1000 iu/10ml Injection, powder, for solution Intravenous 250 iu/5ml Injection, powder, for solution Intravenous 500 iu/5ml Liquid Intravenous 1800 unit / vial Powder, for solution Intravenous 1000 unit / vial Powder, for solution Intravenous 500 unit / vial Injection, powder, lyophilized, for solution; kit Intravenous 1500 [iU]/10mL Injection, powder, lyophilized, for solution; kit Intravenous 250 [iU]/2.5mL Kit Intravenous Kit; solution Intravenous Injection, powder, for solution Intravenous 1000 IU Injection, powder, for solution Intravenous 2000 IU Powder Intravenous 100 IU/mL Powder Intravenous 50 IU/mL Injection, powder, for solution Intravenous 500 iu/10ml Injection, powder, for solution Liquid Intravenous 1000 unit / vial Solution Intravenous Injection, powder, for solution Intravenous 250 iu/vial Injection, powder, for solution Intravenous 500 iu/vial Powder Intravenous Injection, powder, lyophilized, for solution Intravenous Injection, powder, lyophilized, for solution Parenteral Powder, for solution Intravenous Injection, powder, for solution Parenteral Injection, powder, for solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source isoelectric point 5.5-6 United States patent 6953837
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Activator
- General Function
- Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa
- Specific Function
- Calcium ion binding
- Gene Name
- F9
- Uniprot ID
- P00740
- Uniprot Name
- Coagulation factor IX
- Molecular Weight
- 51778.11 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Activator
- General Function
- Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting. Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner (PubMed:24041930, PubMed:30568593, PubMed:34831181). Up-regulates expression of protease-activated receptors (PARs) F2R, F2RL1 and F2RL2 in dermal microvascular endothelial cells (PubMed:35738824). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL6, in cardiac fibroblasts and umbilical vein endothelial cells in PAR-1 (F2R)-dependent manner (PubMed:30568593, PubMed:34831181). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2, IL6, TNF-alpha/TNF, IL-1beta/IL1B, IL8/CXCL8 and IL18, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Induces expression of adhesion molecules, such as ICAM1, VCAM1 and SELE, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Increases expression of phosphorylated ERK1/2 in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Triggers activation of the transcription factor NF-kappa-B in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Up-regulates expression of plasminogen activator inhibitor 1 (SERPINE1) in atrial tissues (PubMed:24041930)
- Specific Function
- Calcium ion binding
- Gene Name
- F10
- Uniprot ID
- P00742
- Uniprot Name
- Coagulation factor X
- Molecular Weight
- 54731.255 Da
References
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids (PubMed:25618265). Exerts a protective effect on the endothelial cell barrier function (PubMed:25651845)
- Specific Function
- Calcium ion binding
- Gene Name
- PROC
- Uniprot ID
- P04070
- Uniprot Name
- Vitamin K-dependent protein C
- Molecular Weight
- 52070.82 Da
References
- Warren DL, Morrissey JH, Neuenschwander PF: Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: generation of an inactive factor VIII cofactor. Biochemistry. 1999 May 18;38(20):6529-36. doi: 10.1021/bi983033o. [Article]
Drug created at June 22, 2017 15:32 / Updated at September 15, 2024 01:12